""washout,""
"LR-1 (100% benign)"
"LR-2 (probably benign)"
"LR-3 (intermediate probability for HCC)"
"LR-4 (probably HCC)"
"LR-5 (100% definite HCC)"
"mass with hepatic arterial phase iso- or hypoenhancement"
"mass with hepatic arterial phase hyperenhancement"
"LR-M for liver lesions that are probably or definitely malignant, but not an appearance compatible with HCC. Examples of this include:"
"LR-NC (LR-non-categorisable) for lesions in which the technical quality of the MRI does not allow evaluation of the major features."
"LR-TIV for unequivocal enhancing soft tissue invading the portal vein, regardless of whether an underlying parenchymal mass is visible. This is important to report since it is a contraindication to liver transplantation. Malignancies other than HCC can invade the portal venous system."
"no more than one"
"two or more of the following"
"one or more of the following"
"one or more of the following"
"no major suspicious features:"
"single major suspicious feature (washout or threshold growth), excluding enhancing "capsule" (LR-4)"
"two or more of the following"
"one or more of the following"
"LR-NC (LR-non-categorisable) for lesions in which the technical quality of the MRI does not allow evaluation of the major features."
"RADS (Reporting and Data Systems)"
Expected headings
"Major criteria"
"Ancillary features"
"Classification"
"LR-1 (100% benign)"
"LR-2 (probably benign)"
"LR-3 (intermediate probability for HCC)"
"LR-4 (probably HCC)"
"LR-5 (100% definite HCC)"
"Special categories"
"CT/MRI Liver Imaging Reporting and Data System (LI-RADS) is an algorithm for diagnosing and staging hepatocellular carcinoma (HCC) (CT/MRI Diagnostic LI-RADS) or assessing the response of HCC to locoregional treatment (CT/MRI Treatment Response LI-RADS) using CT or MRI with extracellular contrast agents or MRI with hepatobiliary contrast agents3."
"only apply this criterion if the lesion is definitely a mass (e.g. not perfusion alteration)"